Belizatinib

SKU: orb1303016

Description

Belizatinib (TSR-011) is a potent, orally bioavailable small molecule that dually inhibits ALK and the TRKA/B/C kinases. It demonstrates activity in cellular assays and has shown antitumor efficacy in preclinical in vivo models of ALK-driven cancers, supporting its use as a research tool in oncology.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1357920-84-3
• MW: 577.73
• Purity: 99.48% (May vary between batches)
• Formula: C₃₃H₄₄FN₅O₃
• SMILES: CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12
• Target: Trk receptor,ALK
• Solubility: DMSO:60 mg/mL (103.85 mM)

Bioactivity

• Target IC50:
  ALK:0.7 nM
• In Vivo:
  In mouse models, Belizatinib can continuously and effectively inhibit ALK-dependent tumor growth.
• In Vitro:
  In the Clinicalal trials, Belizatinib has antitumor activity.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Anaplastic lymphoma kinase (ALK), Anaplastic lymphoma kinase, ALK tyrosine kinase receptor, ALK, Belizatinib, Cluster of differentiation 246, CD246, inhibit, Inhibitor, TSR 011, TSR011, TSR-011, Tropomyosin related kinase receptor, Trk Receptor, Trk receptor, Trkreceptor

Compound Identifiers

PubChem CID

57345941